Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I thought I read something about the ADR ratio changing. Wish I would have held for the gains.
No idea what’s going on
Apparently trading was temporarily halted yesterday?
* * $MTP Video Chart 01-08-2020 * *
Link to Video - click here to watch the technical chart video
Is this going to dump, or climb higher?
Positive results from MTD201-102 Study Supports Subcutaneous Route for Long-Acting Octreotide Product
Press release, dated December 5, 2019 entitled
“Midatech Pharma announces confirmation of a €2.6 million EU Grant for further clinical development of MTX110 for the treatment of Diffuse Intrinsic Pontine Glioma, a rare and fatal form of childhood brain cancer”
Seems to have leveled off. I assume dilution slowed thanks to grant money. Back in.
We may offer and sell from time to time in one or more offerings up to $50,000,000 in aggregate offering price of an indeterminate number of our securities. This prospectus describes the general terms of these securities and the general manner in which these securities will be offered. If we offer securities, we will provide you with a prospectus supplement describing the terms of the specific issue of securities, including the amount, price and terms of the securities. You should read this prospectus and any prospectus supplement carefully before you decide to invest. This prospectus may not be used to sell securities unless it is accompanied by a prospectus supplement that further describes the securities being delivered to you.
We may offer and sell these securities in amounts, at prices and on terms determined at the ti
Read the F-3 from 9/23. $50MM
I think it’s short selling manipulation not dilution
ADR = 20 regular shares. If dilute regular shares, ADR is diluted.
How can they dilute an ADR?
* * $MTP Video Chart 09-20-2019 * *
Link to Video - click here to watch the technical chart video
It was good to see some good news out of the company yesterday. The London shares closed at 8 pence. With 20 shares representing each US share, the 1.60 GBP converts to 2.00 USD. If London holds the current 8 pence price Monday morning, we'll be trading at an 8% discount in the US and can take advantage of the price disparity. At 20M shares in the float and massive volume days at the end of February and April, it looks like 1.50 may offer strong support. Based on those last two big volume days, 3.00 is a decent mid point for some resistance. I'd be real happy with a 60+% run from current levels!
* * $MTP Video Chart 07-19-2019 * *
Link to Video - click here to watch the technical chart video
Pump and dump today. What a shame......
Ok so let them. I have been adding their shares.
Who decides it's time?
You do realize of the 15 mill traded today it only took 500,000 shares to reach the pre-market high of 3.13 and it has trended down since. That is a lot of people underwater. it will bounce somewhere around 1.90 1.70 and maybe reverse up to its opening range but there are so many bagholders who just want to get out
Normal round trip?
Since the RS the trip has been one direction, not round
It’s time to recover some pre RS losses
Not before it does its normal round trip
This is going to $10/share by end of year IMO
This is just the first drug in the pipeline
Still waiting on final approval on all those cancer drugs and delivery systems!
Having bought @$2.24 after open, I was lucky to sell @$2.47, right before the big dump!
Buying back now is tempting but not wise, especially on a Friday...
GLTA
Decided to sell. My greedy $3.00 limit order wasnt close. Chased down to $2.20. GLTA
Some sellers dragging it down. Market cap of ADR lower than London. First I have seen that. Will pop.
I've been trading it all morning. On pullbacks and pops.
Definitely! Super low float
Float is small, could blow past 4$
Wow, are we gonna open over $3? Pre market suggest we may.
$3.02 x $3.04
News release: MTD201 Development Plan
Midatech Pharma PLC (AIM: MTPH.L; Nasdaq: MTP), the R&D company focused on delivering innovative oncology and rare disease products to patients, is pleased to announce that it has finalised the development plan for its key MTD201 Q-Octreotide product, a treatment for acromegaly and neuroendocrine tumours (NET) based on the Company's unique polymer microsphere technology, Q-Sphera™ for sustained drug delivery.
Following consultations with key opinion leaders, regulators, and potential partners, the Company plans to develop MTD201 as a new differentiated product for the treatment of acromegaly and NETs. Midatech has determined that the product characteristics uniquely conferred by Q-Sphera support this positioning of MTD201 to provide the most valuable, de-risked development programme for the Company. A key factor underpinning this decision is the significant competitive advantage and value added as a result of Midatech's Q-Sphera sustained release technology. The technology has patent protection into the 2030's.
As previously reported, the pharmacokinetic and pharmacodynamic profile of MTD201 established in Midatech's 2018 Phase I exploratory study versus market leading Novartis' Sandostatin LAR (SLAR) delivered favourably on the target profile requirements needed compared to current marketed long-acting somatostatin analogues. Additional advantages demonstrated in the study include smaller, less painful needle size, simpler and error free reconstitution and injection, quicker bedside reconstitution (taking less than 10 minutes versus up to 40 minutes for SLAR), reduced wastage and significantly lower manufacturing costs.
Midatech expects further competitive advantages to be leveraged in a differentiated MTD201 product versus other players in the market, such as SLAR, to be:
- subcutaneous, rather than intramuscular, dosing. This is more convenient for patients, allows the potential for self-administration at home rather than having to come into the clinic, and is less painful to patients;
- longer dosing intervals up to 6 weeks, as opposed to 4 weeks for other products; and
- higher doses of up to 60mg compared to current 30mg doses. This means only a single injection is required for higher doses, compared to current octreotide products that require multiple doses that are both painful and very costly.
The next phase of clinical development for MTD201 as a differentiated product is scheduled to commence in H2 2019 to support a first indication in acromegaly. The pivotal registration study in acromegaly patients will seek to compare MTD201 versus placebo and is planned to commence early 2020 following receipt of approval by regulators. Prior to this, Midatech plans a short Phase I study to look to confirm the use of the sub-cutaneous route in the pivotal trial, which the Company believes will provide further significant advantages, as outlined above. The pivotal program, the costs of which are expected to be in-line with the previously stated budget expectations as outlined on 4 February 2019, is expected to conclude in 2021 and, subject to a successful outcome and expected completion on commercial scale-up of MTD201 production at the Company's manufacturing facility in Bilbao, Midatech plans to submit marketing authorisation applications the same year. Subject to funding, a pivotal registration programme to support a second indication in NET is expected to commence in H1 2020.
Commenting, Midatech's Chief Executive Officer, Dr Craig Cook, said: " We are delighted to be able to lay out our roadmap to bring MTD201 to market. Building on the exciting Phase I data and further leveraging the full potential of the Q-Sphera differentiating technology promises a compelling product opportunity for MTD201. The development path has been finalised in close collaboration with our distinguished advisory board, and we believe we have a clear path to potential commercialisation. We look forward to providing regular updates as the development programme progresses."
Looks like shorts are filling today!
Got me some on the drip down. Agreed......
News could send it flying.
Anyone still here? I bought more today... perhaps foolish, but they have been walking down on low volume. Could 3x in one day with news and low float. IMHO. GLTA.
Market cap today is about $42MM, which isn't high for a biotech company at all, but this company has a lot to prove given the timelines that have dragged on. I own shares but considerably underwater today. Hopefully they can turn things around. I'm here for their Q-Sphera platform which has considerable applicability across a huge range of medications and applications.
Well, I guess he created a buying opportunity.
He’s a shorter. That’s why this tumbled so hard after the spike. Clay posts charts bringing in his cronies
Bought more. Big potential....market cap wrong on most sites which may be scaring away investors. See you at $10 in short time. GLTA
You cared enough to respond.
Followers
|
13
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
567
|
Created
|
03/28/16
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |